DE19951471A1 - Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen - Google Patents
Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit NierenrestfunktionenInfo
- Publication number
- DE19951471A1 DE19951471A1 DE19951471A DE19951471A DE19951471A1 DE 19951471 A1 DE19951471 A1 DE 19951471A1 DE 19951471 A DE19951471 A DE 19951471A DE 19951471 A DE19951471 A DE 19951471A DE 19951471 A1 DE19951471 A1 DE 19951471A1
- Authority
- DE
- Germany
- Prior art keywords
- urodilatin
- renal failure
- patients
- chronic renal
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010001957 Ularitide Proteins 0.000 title claims abstract description 24
- 102400001279 Urodilatin Human genes 0.000 title claims abstract description 24
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 title claims abstract description 24
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 11
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 10
- 230000003907 kidney function Effects 0.000 title claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract 2
- 238000000502 dialysis Methods 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 5
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19951471A DE19951471A1 (de) | 1999-10-26 | 1999-10-26 | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| ES00975905T ES2198359T3 (es) | 1999-10-26 | 2000-10-24 | Utilizacion de urodilatina para el tratamiento de insuficiencia renal cronica con funciones renales residuales. |
| AT00975905T ATE239497T1 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
| JP2001532793A JP2003512434A (ja) | 1999-10-26 | 2000-10-24 | 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用 |
| DE50002119T DE50002119D1 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
| EP00975905A EP1223968B1 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
| PCT/EP2000/010462 WO2001030376A2 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
| US10/088,498 US6831064B1 (en) | 1999-10-26 | 2000-10-24 | Use of urodilatin for treating chronic kidney failure with residual kidney functions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19951471A DE19951471A1 (de) | 1999-10-26 | 1999-10-26 | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19951471A1 true DE19951471A1 (de) | 2001-05-03 |
Family
ID=7926884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19951471A Withdrawn DE19951471A1 (de) | 1999-10-26 | 1999-10-26 | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| DE50002119T Expired - Lifetime DE50002119D1 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50002119T Expired - Lifetime DE50002119D1 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6831064B1 (enExample) |
| EP (1) | EP1223968B1 (enExample) |
| JP (1) | JP2003512434A (enExample) |
| AT (1) | ATE239497T1 (enExample) |
| DE (2) | DE19951471A1 (enExample) |
| ES (1) | ES2198359T3 (enExample) |
| WO (1) | WO2001030376A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2554713T3 (es) | 2005-04-07 | 2015-12-22 | Cardiorentis Ag | Uso de un péptido natriurético para tratar insuficiencia cardiaca |
| US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| WO2009034134A2 (en) * | 2007-09-11 | 2009-03-19 | Pharis Biotec Gmbh | Use of natriuretic peptides for treating angioedema syndromes |
| EP2078530A1 (en) | 2008-01-08 | 2009-07-15 | Pharis Biotec GmbH | Use of natriuretic peptides for treating angioedema syndromes |
| EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| EP2948165A2 (en) | 2013-01-25 | 2015-12-02 | Cardiorentis Ltd. | A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications |
| WO2022029497A1 (en) | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Ularitide for use in methods of treating refractory ascites |
| WO2022029499A1 (en) | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Methods of treating refractory ascites |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006596A1 (en) * | 1987-03-02 | 1988-09-07 | Bissendorf Peptide Gmbh | New cardiodilatin fragment, process for preparing same and use thereof |
| US5691310A (en) * | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
| DE4216133A1 (de) * | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
| US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
| US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| DE69734781T2 (de) * | 1996-12-31 | 2006-07-20 | Gupta, Ajay, Cerritos | Verfahren und pharmazeutische zusammensetzung zum zuführen von eisen bei hämodialyse-und peritonealdialysepatienten |
-
1999
- 1999-10-26 DE DE19951471A patent/DE19951471A1/de not_active Withdrawn
-
2000
- 2000-10-24 WO PCT/EP2000/010462 patent/WO2001030376A2/de not_active Ceased
- 2000-10-24 ES ES00975905T patent/ES2198359T3/es not_active Expired - Lifetime
- 2000-10-24 US US10/088,498 patent/US6831064B1/en not_active Expired - Lifetime
- 2000-10-24 EP EP00975905A patent/EP1223968B1/de not_active Expired - Lifetime
- 2000-10-24 DE DE50002119T patent/DE50002119D1/de not_active Expired - Lifetime
- 2000-10-24 AT AT00975905T patent/ATE239497T1/de not_active IP Right Cessation
- 2000-10-24 JP JP2001532793A patent/JP2003512434A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001030376A2 (de) | 2001-05-03 |
| DE50002119D1 (de) | 2003-06-12 |
| JP2003512434A (ja) | 2003-04-02 |
| ES2198359T3 (es) | 2004-02-01 |
| EP1223968B1 (de) | 2003-05-07 |
| ATE239497T1 (de) | 2003-05-15 |
| WO2001030376A3 (de) | 2001-12-06 |
| US6831064B1 (en) | 2004-12-14 |
| EP1223968A2 (de) | 2002-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| VANDER et al. | Mechanism of the effects of furosemide on renin secretion in anesthetized dogs | |
| DE68905203T2 (de) | Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten. | |
| Graf et al. | Disappearance of uraemic pruritus after lowering dialysate magnesium concentration | |
| EP0233279A1 (de) | Neuartige verwendung von taurolin. | |
| DD288094A5 (de) | Verwendung von gamma-interferon zur behandlung von gefaessverengungen | |
| DE69735162T2 (de) | L-carnosin enthaltende mittel zur behandlung von nierenversagen | |
| JP4838139B2 (ja) | 透析液並びに透析液に関連した方法及びシステム | |
| DE19951471A1 (de) | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen | |
| JP2007523056A5 (enExample) | ||
| Faltlhauser et al. | Use of hemoadsorption in a case of severe hepatic failure and hyperbilirubinemia | |
| Mendez et al. | Modulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. | |
| Garg et al. | Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron | |
| Matzkies et al. | The uricosuric action of amino acids in man | |
| EP0331014A2 (de) | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe | |
| DE1951822C3 (de) | Pharmazeutisches Präparat zur Krebsbehandlung | |
| DE69227042T2 (de) | Verfahren und zusammensetzungen zur verminderung von blutverlust | |
| DE202012100195U1 (de) | Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod | |
| RU2227032C2 (ru) | Способ профилактики осложнений при цементном эндопротезировании крупных суставов | |
| JP2020036881A (ja) | 透析装置、アクセプター薬剤、ドナー薬剤、リンス液およびリンス液としての使用方法 | |
| Stankovikj | Acute complications in multiple myeloma | |
| Hotz et al. | Similar modes of action of calcitonin and glucagon in inhibiting pancreatic enzyme secretion in man | |
| Hiatt et al. | Kaluresis and diuresis after administration of antidiuretic hormone to hyperkalemic dogs | |
| Mengel | Antianämika | |
| Naik et al. | WCN25-4621 Cilnidipine–a Novel CCB reduces blood pressure, heart rate and proteinuria in Indian Hypertensive Patients | |
| Orinius | Hyponatremia in congestive heart failure treated with diuretics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |